Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals' stock price has been volatile over the past six months. As of May 7, 2026, the share price was $13.60, a 28.19% decline from the previous year. Key events include the commercial launch of TONMYA in November 2025, a $20.0 million registered direct offering in December 2025, fourth-quarter and full-year 2025 financial results reported in March 2026, securing commercial payer coverage for TONMYA in April-May 2026, and a recent shareholder approval of a reverse stock split.

There is no explicit information indicating significant demand seasonality for Tonix Pharmaceuticals' current commercial products. The migraine products address acute conditions that are not typically seasonal, and TONMYA treats a chronic condition. However, TNX-4800, under development for Lyme disease prevention, would have seasonal demand if successfully commercialized. The company expects to initiate a U.S. field study for TNX-4800 in 2027, pending FDA clearance.

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on therapies for CNS disorders, immunology, immuno-oncology, infectious diseases, and rare diseases. Its portfolio includes commercialized products like TONMYA for fibromyalgia and migraine treatments Zembrace® SymTouch® and Tosymra®. The company has a pipeline of candidates including TNX-102 SL for major depressive disorder and acute stress reaction, TNX-1300 for cocaine intoxication, TNX-1500 for preventing kidney transplant rejection and treating autoimmune conditions, TNX-4800 for Lyme disease prevention, TNX-2900 for Prader-Willi syndrome, TNX-1900 for binge eating disorder, adolescent obesity, bone health in pediatric autism, and arginine-vasopressin deficiency, TNX-801 for smallpox and mpox prevention, TNX-4200 for viral diseases, TNX-4900 for neuropathic pain, TNX-1700 for gastric and colorectal cancers, and TNX-1800 and TNX-1850 for COVID prevention.

Tonix Pharmaceuticals is headquartered in Berkeley Heights, New Jersey, with a corporate office in Chatham, New Jersey. It has a Research and Development Center in Frederick, Maryland, and international subsidiaries in Canada and Ireland. Commercialization efforts for products like TONMYA are focused on the United States.

Tonix Pharmaceuticals has positively impacted its brand reputation through product development and commercialization milestones. The FDA approval and commercial launch of TONMYA as a new fibromyalgia treatment has been a key event. Regular updates on preclinical and clinical programs at scientific conferences enhance its scientific standing. Securing commercial payer coverage for TONMYA strengthens its market position. There is no specific information indicating negative events impacting the company's brand reputation in terms of product safety, ethical concerns, or major controversies in the past year.

Tonix Pharmaceuticals has a mixed ownership structure including institutional, retail, and individual investors. Approximately 6.67% to 14.94% is owned by institutional investors, 0.17% by insiders, and around 84.88% by public companies and retail investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Point72 Asset Management, L.P., among others.